Boston Scientific (BSX)
(Delayed Data from NYSE)
$83.51 USD
-0.49 (-0.58%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $83.51 0.00 (0.00%) 5:20 PM ET
2-Buy of 5 2
C Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.51 USD
-0.49 (-0.58%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $83.51 0.00 (0.00%) 5:20 PM ET
2-Buy of 5 2
C Value B Growth A Momentum B VGM
Zacks News
Senseonics Stock Down Despite New FDA Approval for Eversense 365
by Zacks Equity Research
SENS' latest regulatory clearance is likely to simplify diabetes management with the help of a long-lasting CGM system.
LH Stock Likely to Gain From the Molecular Bioanalytical Lab Expansion
by Zacks Equity Research
Labcorp expands the molecular bioanalytical laboratory in Greenfield, IN.
Reasons to Retain Alcon Stock in Your Portfolio for Now
by Zacks Equity Research
Strong growth in the Surgical and Vision Care businesses raises investors' optimism for ALC.
4 Medical Product Stocks to Buy From a Prospective Industry
by Indrajit Bandyopadhyay
Ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, BAX, HAE and PAHC are well-poised to gain from the favorable factors.
Boston Scientific (BSX) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
Boston Scientific (BSX) closed at $84 in the latest trading session, marking a +0.1% move from the prior day.
TNDM Stock Likely to Benefit From the t:slim X2-Lyumjev Offering in EU
by Zacks Equity Research
Tandem Diabetes' t:slim X2 insulin pump is now compatible with Lilly's Lyumjev in the European Union.
Here's How Much You'd Have If You Invested $1000 in Boston Scientific a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Is Boston Scientific (BSX) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Boston Scientific (BSX) possesses solid growth attributes, which could help it handily outperform the market.
Boston Scientific (BSX) Is Up 2.10% in One Week: What You Should Know
by Zacks Equity Research
Does Boston Scientific (BSX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Boston Scientific (BSX) Is a Good Investment: Is It?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Boston Scientific Corporation (BSX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Boston Scientific (BSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Innovation Aids Alcon Stock's Growth Despite Macroeconomic Troubles
by Zacks Equity Research
Banking on strong sales of its contact lenses and ocular health products, ALC is registering solid growth within Vision Care.
DGX Stock to Benefit From New Partnership With Sentara Health Plans
by Zacks Equity Research
Quest Diagnostics extends services in Virginia and Florida via a partnership with Sentara Health Plans.
MMSI Stock Likely to Gain From Cook Medical's Product Portfolio Buyout
by Zacks Equity Research
Merit Medical expects to solidify its foothold in the underpenetrated global lead management market via the latest asset acquisition.
Here's Why You Should Retain Integer Holdings Stock in Your Portfolio Now
by Zacks Equity Research
ITGR's research and product development activities raise optimism about the stock. Rising demand for its products bodes well for the company.
TMO Stock to Gain From Expanded Bioanalytical Services in Sweden
by Zacks Equity Research
Thermo Fisher's PPD arm unveils a new facility in Sweden, expanding its bioanalytical capabilities.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Reasons to Retain EYE Stock in Your Portfolio for Now
by Zacks Equity Research
The strong execution of strategic initiatives and robust market expansion of the Owned and Host segment bode well for National Vision.
Is Teleflex Stock a Smart Option for Your Portfolio Right Now?
by Zacks Equity Research
TFX instils optimism with its robust performance in the Interventional category and potential in Asia.
MASI Stock Gains as US Court Raises Concern About Politan's Ethics
by Zacks Equity Research
Shares of Masimo have risen since the news of a court ruling against Politan. The ruling is likely to favor MASI's founder in the upcoming vote for new board members on Sept. 19.
Stryker Stock Declines Despite Completion of care.ai Acquisition
by Zacks Equity Research
SYK completes the acquisition of care.ai, adding AI-based workflows and smart room technology to its portfolio to overcome nursing shortages, and improve staff retention and workplace safety.
Here's Why Boston Scientific (BSX) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BSX Gets FDA Nod on INGEVITY+ Pacing Lead in the LBBA: Stock to Gain?
by Zacks Equity Research
Boston Scientific received FDA approval on the expanded indication for INGEVITY+ Pacing Leads. Data demonstrated this lead to be safe and effective for LBBA pacing.
CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA
by Zacks Equity Research
Charles River collaborates with CEBINA as part of the DanubeNeuro program to advance innovation in neurodegeneration.
Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Boston Scientific (BSX) closed the most recent trading day at $82.52, moving -1.19% from the previous trading session.